Exhibit 99.1 Ocular Therapeutix™ Reports First Quarter 2024 Results Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, MA, May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeut ...